Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 9/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | MARS1 | P56192 | 1/20 | 0.39 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.38 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.38 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.38 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.38 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.38 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.38 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.38 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22005071 | 0.84 | ACLY (0.47) | ACLYCYP3A4MAPTTHRB | |
| SCHEMBL22004377 | 0.83 | ACLY (0.54) | ACLYDHODHMARS1HSD11B1CHRNA7 | |
| SCHEMBL22004166 | 0.82 | ACLY (0.53) | ACLYCYP3A4MAPTTHRB | |
| SCHEMBL22003798 | 0.78 | ACLY (0.44) | ACLYMAPTTHRB | |
| SCHEMBL22021799 | 0.77 | ACLY (0.48) | ACLYATP1A1ATP1B1ATP1A3ATP1B2 | |
| SCHEMBL22004395 | 0.76 | KCNH2 (0.45) | ACLYGCGRMAPTTHRB | |
| SCHEMBL22004330 | 0.75 | ACLY (0.50) | ACLYMAPTTHRB | |
| SCHEMBL22004112 | 0.74 | ACLY (0.57) | ACLY | |
| SCHEMBL22003807 | 0.73 | ACLY (0.47) | ACLYMAPTTHRB | |
| SCHEMBL22004122 | 0.72 | ACLY (0.46) | ACLYMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020102616-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | ACLY 1/4885DHODH 219/4885MARS1 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.